Moleculin Biotech, Inc.

NasdaqCM:MBRX 주식 보고서

시가총액: US$7.0m

Moleculin Biotech 관리

관리 기준 확인 3/4

Moleculin Biotech CEO는 Wally Klemp, Jul2015 에 임명되었습니다 의 임기는 9.33 년입니다. 총 연간 보상은 $ 1.41M, 39.9% 로 구성됩니다. 39.9% 급여 및 60.1% 보너스(회사 주식 및 옵션 포함). 는 $ 178.69K 가치에 해당하는 회사 주식의 2.56% 직접 소유합니다. 178.69K. 경영진과 이사회의 평균 재임 기간은 각각 7.1 년과 7.3 년입니다.

주요 정보

Wally Klemp

최고 경영자

US$1.4m

총 보상

CEO 급여 비율39.9%
CEO 임기9.3yrs
CEO 소유권2.6%
경영진 평균 재임 기간7.1yrs
이사회 평균 재임 기간7.3yrs

최근 관리 업데이트

Recent updates

We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Dec 20
We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Jul 14
Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Feb 18
Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Nov 01
Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies

Sep 27

Moleculin brain cancer therapy WP1122 gets FDA orphan drug status

Sep 06

Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Jul 11
Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

Jul 08

We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth

Mar 28
We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth

We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Dec 11
We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth

Aug 18
We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth

Moleculin Biotech to join Russell 2000 Index

Jun 15

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth?

May 04
Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth?

Moleculin shares soar after promising Annamycin pre-clinical readout

Feb 02

Moleculin Biotech under pressure on reverse stock split

Jan 29

Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Jan 15
Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Bio's Annamycin an Orphan Drug in U.S. for soft tissue sarcomas

Dec 29

CEO 보상 분석

Wally Klemp 의 보수는 Moleculin Biotech 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$25m

Mar 31 2024n/an/a

-US$27m

Dec 31 2023US$1mUS$565k

-US$30m

Sep 30 2023n/an/a

-US$26m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$2mUS$565k

-US$29m

Sep 30 2022n/an/a

-US$25m

Jun 30 2022n/an/a

-US$21m

Mar 31 2022n/an/a

-US$18m

Dec 31 2021US$2mUS$538k

-US$16m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021n/an/a

-US$15m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020US$2mUS$500k

-US$17m

Sep 30 2020n/an/a

-US$19m

Jun 30 2020n/an/a

-US$19m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019US$2mUS$625k

-US$13m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$10m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$1mUS$403k

-US$12m

Sep 30 2018n/an/a

-US$12m

Jun 30 2018n/an/a

-US$13m

Mar 31 2018n/an/a

-US$11m

Dec 31 2017US$1mUS$325k

-US$10m

보상 대 시장: Wally 의 총 보상 ($USD 1.41M )은 US 시장( $USD 653.78K ).

보상과 수익: Wally 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Wally Klemp (64 yo)

9.3yrs

테뉴어

US$1,414,599

보상

Mr. Walter V. Klemp, also known as Wally, has been the Executive Chairman of Autonomix Medical, Inc. since joining in January 2022. He Co-Founded Moleculin Biotech, Inc. in July 2015 and has been its Chief...

리더십 팀

이름위치테뉴어보상소유권
Walter Klemp
Co-Founder9.3yrsUS$1.41m2.56%
$ 178.7k
Jonathan Foster
Executive VP & CFO8.3yrsUS$840.64k0.40%
$ 27.8k
Donald Picker
Chief Scientific Officer7.3yrsUS$599.11k0.28%
$ 19.6k
Waldemar Priebe
Co-Founderno data데이터 없음데이터 없음
John Waymack
Senior Chief Medical Officer3.1yrs데이터 없음데이터 없음
Sandra Silberman
Chief Medical Officer of New Products7yrs데이터 없음데이터 없음
Wolfram C. Dempke
European Chief Medical Officer2.5yrs데이터 없음데이터 없음

7.1yrs

평균 재임 기간

69yo

평균 연령

경험이 풍부한 관리: MBRX 의 관리팀은 노련하고 경험 (평균 재직 기간 7.1 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Walter Klemp
Co-Founder9.3yrsUS$1.41m2.56%
$ 178.7k
Waldemar Priebe
Co-Founderno data데이터 없음데이터 없음
Michael Cannon
Independent Director8.4yrsUS$68.52k0%
$ 0
John Climaco
Lead Independent Director7.3yrsUS$81.05k0%
$ 0
Elizabeth Cermak
Independent Director4.1yrsUS$63.52k0%
$ 0
Martin Tallman
Member of Annamycin Scientific Advisory Boardless than a year데이터 없음데이터 없음
Robert George
Independent Director8.4yrsUS$74.90k0.034%
$ 2.4k
Joy Yan
Independent Director2.7yrsUS$47.15k0%
$ 0

7.3yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: MBRX 의 이사회는 경험(평균 재직 기간 7.3 년)으로 간주됩니다.